New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 12, 2012
14:19 EDTIPXLFDA delay of Impax's Rytary should have little impact on outlook, says Needham
After the FDA extended the PDUFA for Impax's Rytary by three months but didn't request any new clinical trials, Needham expects the move to little impact on the outlook of investors, who had expected the drug to be approved with little difficulty. The firm expects the drug to be approved but believes that peak sales will be below the company's guidance. Needham maintains a Hold rating on the shares.
News For IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
07:32 EDTIPXLImpax granted EC marketing authorization for Numient
Impax announced that the European Commission has granted marketing authorization for Numient, a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease. The review of this application was conducted under the centralized licensing procedure as a therapeutic innovation, and is applicable in all 28 member states of the European Union, as well as Iceland, Liechtenstein and Norway. The EC decision is based on results from three Phase 3 controlled clinical studies which assessed the safety and efficacy of Numient in patients with early and advanced Parkinson's disease in the U.S. and in Europe.
06:04 EDTIPXLMylan and Perrigo set to face-off over potential targets, Bloomberg reports
Mylan (MYL) will likely find itself now competing with Perrigo (PRGO) for other assets, reports Bloomberg. According to Bloomberg Intelligence analyst Elizabeth Krutoholow, both companies may look to buy Impax Laboratories (IPXL), Stada Arzneimittel or Taro Pharmaceutical Industries (TARO). All of the potential targets are attractive due to their over-the-counter products. Reference Link
November 24, 2015
09:05 EDTIPXLImpax receives FDA approval for generic version of dutasteride capsules
Subscribe for More Information
November 16, 2015
07:16 EDTIPXLHayman Capital gives quarterly update on stakes
NEW STAKES: Impax (IPXL), CF Industries (CF), GW Pharmaceuticals (GWPH), ProNAi Therapeutics (DNAI). INCREASED STAKES: BioMarin (BMRN), NMI Holdings (NMIH), Vertex (VRTX), Endo (ENDP). DECREASED STAKES: Mylan (MYL). LIQUIDATED STAKES: Perrigo (PRGO), Oasis Petroleum (OAS), Whiting Petroleum (WLL), Newfield Exploration (NFX), SM Energy (SM).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use